Navigation Links
Novelos Therapeutics and MUSC Present Two Posters at AACR 2007,Annual Meeting

NEWTON, Mass.--(BUSINESS WIRE)--Apr 16, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the company, in collaboration with Dr. Kenneth Tew and Dr. Danyelle Townsend of the Medical University of South Carolina (MUSC), is making two poster presentations at the ongoing American Association for Cancer Research annual meeting. These presentations will highlight in vivo and in vitro findings with NOV-002, which is currently in a pivotal Phase 3 trial for non-small cell lung cancer and Phase 2 trials for other oncology indications. The posters are available at www.novelos.com 'Our Products', 'NOV-002' section.

"As clinical development of NOV-002 progresses, we continue to add to our understanding of its molecular and cellular mechanisms of action as they may relate to therapeutic activity," said Christopher Pazoles, Ph.D., Vice President of Research & Development of Novelos. "Our ongoing and broad-ranging research collaboration with Drs. Tew and Townsend at MUSC is an important part of that effort."

About Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and an immunomodulator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer, and is in addition being developed for acute radiation injury. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed. For additional information about Novelos please visit www.novelos.com

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.

Contact

Novelos Therapeutics, Inc.
Harry S. Palmin, 617-244-1616 x11
President and CEO
hpalmin@novelos.com
or
Investor Relations:
Stephen Lichaw, 201-240-3200
slichaw@novelos.com


'"/>




Related medicine technology :

1. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... Infusion Group, a brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has ... location. The Iowa facility ... cleanroom—the standard needed to compound intravenous (IV) nutrition formulations. A cleanroom ... "Our new cleanroom will allow us ... Iowa patients," said Phil Rielly , Diplomat ...
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
(Date:5/26/2017)...  Endo International plc (NASDAQ: ENDP ) announced ... represent the Company in a fireside chat at Goldman Sachs, ... 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ET. ... Rancho Palos Verdes, CA. A ... available on the Company,s website at http://www.endo.com/investors/overview . Participants ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... June 23, 2017 , ... Despite its pervasiveness, many ... reviews available that integrate basic science with clinical practice. Now, however, a timely review ... providing clinicians with insight into the etiology of NeuP and educating preclinical scientists on ...
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... A June ... Rittenberg to a correspondent concerned about an apparent lack of oral hygiene by an ... specializes in geriatrics and dementia-related matters, suggests a number of steps, including scheduling a ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... CHRISTUS Health, a Texas-based health system, will present how predictive analytics drive reimbursement ... HFMA ANI meeting in Orlando, June 25-28. , “The traditional approach to ...
(Date:6/20/2017)... Gainesville, FL (PRWEB) , ... June 20, 2017 ... ... interactive health science curriculum , is pleased to announce a new online ... The accredited online course provides practical insights and evidence-based strategies for achieving optimal ...
(Date:6/20/2017)... ... ... Kenneth Mayer, MD, has been appointed a new Editor-in-Chief of the ... JIAS Editorial Board in 2016, has co-authored more than 800 peer-reviewed publications. Among his ... and Co-Chair of The Fenway Institute, a member of the US President’s Emergency Plan ...
Breaking Medicine News(10 mins):